Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538871 | 0.84 | MAOB (0.47) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL9705393 | 0.79 | NOTUM (0.45) | NOTUMMEN1KMT2AEGFRABCG2 | |
| SCHEMBL11753299 | 0.77 | NOTUM (0.44) | NOTUMKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL8441892 | 0.74 | KDM4E (0.52) | NOTUMKMT2AMAP2K1KDM4EALDH1A1 | |
| SCHEMBL5212912 | 0.71 | ALDH1A1 (0.42) | NOTUMMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7367312 | 0.69 | ALDH1A1 (0.47) | NOTUMMEN1KMT2AEGFRABCG2 | |
| SCHEMBL17260662 | 0.69 | PDE3B (0.63) | NOTUMMEN1KMT2AEGFRKDM4E | |
| SCHEMBL17260649 | 0.69 | PDE3B (0.63) | NOTUMMEN1KMT2AEGFRKDM4E | |
| SCHEMBL6603063 | 0.68 | MAP2K1 (0.54) | NOTUMMEN1KMT2AEGFRMAP2K1 | |
| SCHEMBL7278194 | 0.68 | NOTUM (0.45) | NOTUMNPC1RAB9AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | NOTUM 704/4885MEN1 4420/4885KMT2A 3081/4885 |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | NOTUM 542/4885MEN1 1635/4885KMT2A 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.